MX2020006594A - Inhibidores de exo-azaespiro de la interaccion menina-mll. - Google Patents

Inhibidores de exo-azaespiro de la interaccion menina-mll.

Info

Publication number
MX2020006594A
MX2020006594A MX2020006594A MX2020006594A MX2020006594A MX 2020006594 A MX2020006594 A MX 2020006594A MX 2020006594 A MX2020006594 A MX 2020006594A MX 2020006594 A MX2020006594 A MX 2020006594A MX 2020006594 A MX2020006594 A MX 2020006594A
Authority
MX
Mexico
Prior art keywords
menin
inhibitors
exo
aza spiro
mll interaction
Prior art date
Application number
MX2020006594A
Other languages
English (en)
Inventor
Patrick René Angibaud
Virginie Sophie Poncelet
Olivier Alexis Georges Querolle
Wei Cai
Vineet Pande
Daniel Jason Krosky
Aaron Nathaniel Patrick
James Patrick Edwards
Xuedong Dai
Liqiang Fu
Linglong Kong
Yingtao Liu
Zhao - Kui WAN
Geb Herkert Barbara Morschhäuser
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2020006594A publication Critical patent/MX2020006594A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a agentes farmacéuticos útiles para terapia y/o profilaxis en un mamífero, composición farmacéutica que comprende dichos compuestos, y su uso como inhibidores de la interacción proteína/proteína menina/MLL, útiles para tratar enfermedades tales como cáncer, síndrome mielodisplásico (MDS) y diabetes.
MX2020006594A 2017-12-20 2018-12-19 Inhibidores de exo-azaespiro de la interaccion menina-mll. MX2020006594A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017117536 2017-12-20
CN2018091521 2018-06-15
PCT/CN2018/121960 WO2019120209A1 (en) 2017-12-20 2018-12-19 Exo-aza spiro inhibitors of menin-mll interaction

Publications (1)

Publication Number Publication Date
MX2020006594A true MX2020006594A (es) 2020-09-09

Family

ID=66993097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006594A MX2020006594A (es) 2017-12-20 2018-12-19 Inhibidores de exo-azaespiro de la interaccion menina-mll.

Country Status (12)

Country Link
US (1) US20230039917A1 (es)
EP (1) EP3728260A4 (es)
JP (1) JP7307729B2 (es)
KR (1) KR20200101389A (es)
CN (1) CN111601807B (es)
AU (1) AU2018389145B2 (es)
BR (1) BR112020012461A2 (es)
CA (1) CA3083624A1 (es)
IL (1) IL275457A (es)
MA (1) MA51337A (es)
MX (1) MX2020006594A (es)
WO (1) WO2019120209A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110950818B (zh) * 2019-12-18 2021-12-28 浙江海翔药业股份有限公司 顺式-2,6-二甲基吗啉的纯化方法
CN114478568A (zh) * 2020-10-27 2022-05-13 苏州优理生物医药科技有限公司 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用
KR20230157981A (ko) * 2021-02-19 2023-11-17 칼비스타 파마슈티컬즈 리미티드 인자 xiia 저해제
BR112023023154A2 (pt) 2021-05-08 2024-01-23 Janssen Pharmaceutica Nv Derivados espiro substituídos
KR20240005747A (ko) 2021-05-08 2024-01-12 얀센 파마슈티카 엔브이 치환된 스피로 유도체
EP4337203A1 (en) * 2021-05-14 2024-03-20 Syndax Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904612A1 (en) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
AR104020A1 (es) * 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
US20190010167A1 (en) * 2015-12-22 2019-01-10 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
WO2017207387A1 (en) * 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
SI3468966T1 (sl) * 2016-06-10 2021-03-31 Vitae Pharmaceuticals, Llc Zaviralci interakcije menin-MLL
CA3033239A1 (en) * 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
US11396517B1 (en) * 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction

Also Published As

Publication number Publication date
KR20200101389A (ko) 2020-08-27
JP2021506882A (ja) 2021-02-22
IL275457A (en) 2020-08-31
CA3083624A1 (en) 2019-06-27
EP3728260A4 (en) 2021-08-11
MA51337A (fr) 2020-10-28
AU2018389145A1 (en) 2020-05-21
JP7307729B2 (ja) 2023-07-12
CN111601807A (zh) 2020-08-28
RU2020123548A3 (es) 2022-02-17
WO2019120209A1 (en) 2019-06-27
BR112020012461A2 (pt) 2020-11-24
US20230039917A1 (en) 2023-02-09
RU2020123548A (ru) 2022-01-20
AU2018389145B2 (en) 2023-02-02
EP3728260A1 (en) 2020-10-28
CN111601807B (zh) 2023-03-31

Similar Documents

Publication Publication Date Title
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
EA201990699A1 (ru) Спиробициклические ингибиторы взаимодействия менин–mll
MX2019002959A (es) Inhibidores biciclicos condensados de la interaccion de menina-mll.
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12020550901A1 (en) Macrocyclic compounds for treating disease
CA2999253C (en) Heterocyclic compounds and uses thereof
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
NZ719905A (en) Bicyclic heterocycle compounds and their uses in therapy
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
EA201991448A1 (ru) Азепановые ингибиторы взаимодействия менин-mll
TR201908265T4 (tr) Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri.
MX2020000135A (es) Nuevos compuestos de quinolinona.
PH12021551280A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2017012102A (es) Agentes citotoxicos bifuncionales que contienen el farmacoforo de cti.
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201790349A1 (ru) Производные 6-алкинил-пиридина в качестве миметиков белка smac
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
MX2019007067A (es) Inhibidores de azepano de la interacción menina-mll.
WO2016187620A3 (en) Anti-cancer compounds